Viamet Pharmaceuticals, Inc. announced today that it has secured $18 million in a Series B financing to accelerate the development of its novel metalloenzyme inhibitors and to advance its MetallophileTM Technology platform.
Fatal error: Call to undefined function add_submit_it() in /home/.lodi/hayblogone/venture.name/wp-content/themes/adsminded/single.php on line 24